SAG
BBIO icon

SageView Advisory Group’s BridgeBio Pharma BBIO Stock Holding History

SageView Advisory Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,344
Closed -$179K – 755
2025
Q4 		$179K Buy
+2,344
New +$154K 0.01% 633

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SageView Advisory Group's BBIO Position: Q1 2026 in Review

SageView Advisory Group sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 2,344 shares — an estimated $179K sold.

SageView Advisory Group first reported a position in BBIO in Q4 2025 and held it in 1 quarter. The position peaked at $179K in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • SageView Advisory Group reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 2,344 BridgeBio Pharma shares in Q1 2026, an estimated $179K.
  • SageView Advisory Group first reported a position in BridgeBio Pharma in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's BridgeBio Pharma position peaked at $179K in Q4 2025.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.